600867 通化东宝
已收盘 03-10 15:00:00
资讯
新帖
简况
每周股票复盘：通化东宝（600867）回购进展支付超2757万元
证券之星 · 02-08
每周股票复盘：通化东宝（600867）回购进展支付超2757万元
通化东宝收警示函背后：控股股东质押率超94%，12亿净利难掩转型焦虑
市场资讯 · 02-04
通化东宝收警示函背后：控股股东质押率超94%，12亿净利难掩转型焦虑
2月2日通化东宝跌5.30%，博时中证1000指数增强A基金重仓该股
证券之星 · 02-02
2月2日通化东宝跌5.30%，博时中证1000指数增强A基金重仓该股
通化东宝药业被责令改正，董事长被出具警示函，涉独立性不足
蓝鲸财经 · 02-01
通化东宝药业被责令改正，董事长被出具警示函，涉独立性不足
每周股票复盘：通化东宝（600867）2025年预盈12.42亿元
证券之星 · 02-01
每周股票复盘：通化东宝（600867）2025年预盈12.42亿元
通化东宝（600867）股东东宝实业集团股份有限公司质押2100万股，占总股本1.07%
证券之星 · 01-31
通化东宝（600867）股东东宝实业集团股份有限公司质押2100万股，占总股本1.07%
最高4379%！6家A股公司净利同比预增超10倍
21世纪经济报道 · 01-28
最高4379%！6家A股公司净利同比预增超10倍
通化东宝：预计2025年全年扣非后净利润盈利约4.02亿元
证券之星 · 01-26
通化东宝：预计2025年全年扣非后净利润盈利约4.02亿元
通化东宝预计2025年将实现净利润约12亿元
美股速递 · 01-26
通化东宝预计2025年将实现净利润约12亿元
每周股票复盘：通化东宝（600867）东宝集团质押股份占总股本29.33%
证券之星 · 01-18
每周股票复盘：通化东宝（600867）东宝集团质押股份占总股本29.33%
通化东宝（600867）披露控股股东股份解押及再质押公告，1月16日股价下跌0.7%
证券之星 · 01-16
通化东宝（600867）披露控股股东股份解押及再质押公告，1月16日股价下跌0.7%
通化东宝（600867）公司公告聘任高级管理人员，1月15日股价上涨0.47%
证券之星 · 01-15
通化东宝（600867）公司公告聘任高级管理人员，1月15日股价上涨0.47%
通化东宝（600867）披露关于审计机构变更签字项目合伙人、签字注册会计师的公告，1月8日股价上涨0.24%
证券之星 · 01-08
通化东宝（600867）披露关于审计机构变更签字项目合伙人、签字注册会计师的公告，1月8日股价上涨0.24%
通化东宝（600867）股东东宝实业集团股份有限公司质押4200万股，占总股本2.14%
证券之星 · 01-07
通化东宝（600867）股东东宝实业集团股份有限公司质押4200万股，占总股本2.14%
通化东宝（600867）披露以集中竞价交易方式回购公司股份进展公告，1月5日股价上涨2.57%
证券之星 · 01-05
通化东宝（600867）披露以集中竞价交易方式回购公司股份进展公告，1月5日股价上涨2.57%
每周股票复盘：通化东宝（600867）控股股东累计质押占总股本28.72%
证券之星 · 01-02
每周股票复盘：通化东宝（600867）控股股东累计质押占总股本28.72%
通化东宝（600867）股东东宝实业集团股份有限公司质押4950万股，占总股本2.53%
证券之星 · 2025-12-30
通化东宝（600867）股东东宝实业集团股份有限公司质押4950万股，占总股本2.53%
通化东宝（600867）披露研发生产系统员工持股计划完成股票非交易过户，12月29日股价下跌1.44%
证券之星 · 2025-12-29
通化东宝（600867）披露研发生产系统员工持股计划完成股票非交易过户，12月29日股价下跌1.44%
通化东宝（600867）披露研发生产系统员工持股计划草案，12月4日股价下跌0.68%
证券之星 · 2025-12-04
通化东宝（600867）披露研发生产系统员工持股计划草案，12月4日股价下跌0.68%
通化东宝（600867）披露以集中竞价交易方式回购公司股份进展公告，12月02日股价下跌0.23%
证券之星 · 2025-12-02
通化东宝（600867）披露以集中竞价交易方式回购公司股份进展公告，12月02日股价下跌0.23%
暂无数据
公司概况
公司名称：
通化东宝药业股份有限公司
所属行业：
医药制造业
上市日期：
1994-08-24
主营业务：
通化东宝药业股份有限公司的主营业务是糖尿病及内分泌治疗领域生物制品、中成药、化学药等药品的研发、生产和销售。公司的主要产品是人胰岛素原料药、人胰岛素注射剂（注册商标：甘舒霖）、甘精胰岛素原料药、甘精胰岛素注射液（注册商标：平舒霖）、门冬胰岛素原料药、门冬胰岛素注射液、预混型门冬胰岛素（门冬胰岛素30注射液与门冬胰岛素50注射液）（注册商标：锐舒霖）、利拉鲁肽注射液（注册商标：统博力）、恩格列净片（注册商标：唐捷恩）、镇脑宁胶囊、糖尿病。公司被国家认定为高新技术企业、国家技术创新示范企业。
发行价格：
6.50
{"stockData":{"symbol":"600867","market":"SH","secType":"STK","nameCN":"通化东宝","latestPrice":9.17,"timestamp":1773126000000,"preClose":8.93,"halted":0,"volume":50350563,"delay":0,"changeRate":0.0269,"floatShares":1959000000,"shares":1959000000,"eps":0.626,"marketStatus":"已收盘","change":0.24,"latestTime":"03-10 15:00:00","open":8.96,"high":9.22,"low":8.94,"amount":459000000,"amplitude":0.0314,"askPrice":9.18,"askSize":1009,"bidPrice":9.17,"bidSize":2599,"shortable":0,"etf":0,"ttmEps":0.626,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773192600000},"marketStatusCode":5,"adr":0,"adjPreClose":8.93,"symbolType":"stock","openAndCloseTimeList":[[1773106200000,1773113400000],[1773118800000,1773126000000]],"highLimit":9.82,"lowLimit":8.04,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1958542829,"isCdr":false,"pbRate":2.52,"roa":"--","peRate":14.648562,"roe":"17.77%","epsLYR":-0.02,"committee":-0.426267,"marketValue":17960000000,"turnoverRate":0.0257,"status":0,"floatMarketCap":17960000000},"requestUrl":"/m/hq/s/600867/tweets","defaultTab":"tweets","newsList":[{"id":"2609252373","title":"每周股票复盘：通化东宝（600867）回购进展支付超2757万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609252373","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609252373?lang=zh_cn&edition=full","pubTime":"2026-02-08 01:30","pubTimestamp":1770485432,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，通化东宝报收于8.91元，较上周的9.05元下跌1.55%。本周，通化东宝2月5日盘中最高价报9.24元。本周关注点公司公告汇总：截至2026年1月末，累计支付27,574,286.00元回购股份公司公告汇总通化东宝药业股份有限公司于2025年10月17日召开董事会，审议通过以集中竞价交易方式回购公司股份的方案，回购资金总额不低于2,000万元且不超过4,000万元，回购价格不超过10元/股，回购期限为2025年10月17日至2026年4月16日。上述进展符合相关规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600867","BK0239","BK0196"],"gpt_icon":0},{"id":"2608552053","title":"通化东宝收警示函背后：控股股东质押率超94%，12亿净利难掩转型焦虑","url":"https://stock-news.laohu8.com/highlight/detail?id=2608552053","media":"市场资讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608552053?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:01","pubTimestamp":1770192060,"startTime":"0","endTime":"0","summary":" 2026年1月30日，通化东宝药业股份有限公司发布公告称，收到吉林证监局下发的行政监管措施决定书。决定书指出，通化东宝与控股股东东宝实业集团股份有限公司存在部分房产互相混用情况，双方未签订相关租赁协议，也未支付租金。吉林证监局决定对公司采取责令改正措施，对董事长李佳鸿出具警示函，并将相关情况记入证券期货市场诚信档案。 通化东宝与控股股东之间的房产混用问题，暴露出公司在独立性方面的缺陷。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2026-02-04/doc-inhkrtwm6663771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","600867","BK0188","BK0196"],"gpt_icon":0},{"id":"2608185904","title":"2月2日通化东宝跌5.30%，博时中证1000指数增强A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2608185904","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608185904?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:35","pubTimestamp":1770021303,"startTime":"0","endTime":"0","summary":"证券之星消息，2月2日通化东宝跌5.30%，收盘报8.57元，换手率3.43%，成交量67.12万手，成交额5.85亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为博时基金的博时中证1000指数增强A。博时中证1000指数增强A目前规模为3.89亿元，最新净值1.6771，较上一交易日下跌1.04%，近一年上涨50.8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200023258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000300.SH","399001","000688.SH","510880","600867","BK0188","159967","BK0196","510300","BK0239","512510","399006","512880","000905.SH","515890"],"gpt_icon":0},{"id":"2608001082","title":"通化东宝药业被责令改正，董事长被出具警示函，涉独立性不足","url":"https://stock-news.laohu8.com/highlight/detail?id=2608001082","media":"蓝鲸财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608001082?lang=zh_cn&edition=full","pubTime":"2026-02-01 16:19","pubTimestamp":1769933978,"startTime":"0","endTime":"0","summary":"蓝鲸新闻2月1日讯，近日，吉林证监局发布行政监管措施决定书，剑指通化东宝药业股份有限公司、李佳鸿。决定书显示，通化东宝药业股份有限公司存在以下问题：通化东宝与控股股东东宝实业集团股份有限公司存在部分房产互相混用情况，双方未签订相关租赁协议，未支付租金。上述事项反映出通化东宝独立性存在不足，违反了《上市公司治理准则》有关规定，公司董事长李佳鸿对上述违规行为负主要责任。对此，吉林证监局决定对通化东宝药业股份有限公司采取责令改正，对李佳鸿采取出具警示函的监督管理措施，并记入证券期货市场诚信档案。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1769781247225369242","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0188","BK0196","BK0239","600867"],"gpt_icon":0},{"id":"2608297072","title":"每周股票复盘：通化东宝（600867）2025年预盈12.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608297072","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608297072?lang=zh_cn&edition=full","pubTime":"2026-02-01 01:52","pubTimestamp":1769881930,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，通化东宝报收于9.05元，较上周的8.9元上涨1.69%。公司公告汇总：公司2025年四季度计提减值损失合计1.34亿元，减少当期利润总额。业绩披露要点通化东宝发布业绩预告，预计2025年全年归属净利润盈利约12.42亿元。公司公告汇总通化东宝预计2025年年度实现归属于母公司所有者的净利润约为124,213万元，与上年同期相比实现扭亏为盈。东宝集团及其一致行动人合计持有公司股份641,362,975股，占公司总股本的32.75%，累计质押股份占其持股总数的91.44%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600867","BK0196","BK0239","BK0188"],"gpt_icon":0},{"id":"2607440028","title":"通化东宝（600867）股东东宝实业集团股份有限公司质押2100万股，占总股本1.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607440028","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607440028?lang=zh_cn&edition=full","pubTime":"2026-01-31 00:17","pubTimestamp":1769789843,"startTime":"0","endTime":"0","summary":"证券之星消息，通化东宝1月31日公开信息显示，股东东宝实业集团股份有限公司向中国建设银行股份有限公司通化分行合计质押2100.0万股，占总股本1.07%。质押详情见下表：截止本公告日，股东东宝实业集团股份有限公司已累计质押股份5.86亿股，占其持股总数的94.66%。通化东宝主营业务：药品研发、生产和销售,主要业务涵盖生物制品、中成药、化学药,治疗领域以糖尿病及内分泌、心脑血管为主。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013100000155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","BK0188","600867"],"gpt_icon":0},{"id":"2606982777","title":"最高4379%！6家A股公司净利同比预增超10倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2606982777","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606982777?lang=zh_cn&edition=full","pubTime":"2026-01-28 15:29","pubTimestamp":1769585351,"startTime":"0","endTime":"0","summary":"作为业绩预增榜首，宁波富邦在1月27日晚披露的业绩预告中表示，预计2025年度实现归属于母公司所有者的净利润为5000万元到7000万元，与上年同期相比，将增加4843.73万元到6843.73万元，同比将增长3099.59%到4379.43%。整体看，A股已发布业绩预告的公司中，2025年度净利同比预增超100%有253家，其中有123家扭亏、130家预增。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128153218a6b63e20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128153218a6b63e20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1592","01772","BK1509","BK1594","300850","300871","SG9999003461.SGD","600768","BK1129","SG9999006597.SGD","600867","002553","601388","BK1190"],"gpt_icon":0},{"id":"2606219416","title":"通化东宝：预计2025年全年扣非后净利润盈利约4.02亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606219416","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606219416?lang=zh_cn&edition=full","pubTime":"2026-01-26 18:33","pubTimestamp":1769423618,"startTime":"0","endTime":"0","summary":"证券之星消息，通化东宝发布业绩预告，预计2025年全年扣非后净利润盈利约4.02亿元。通化东宝2025年三季报显示，前三季度公司主营收入21.8亿元，同比上升50.55%；归母净利润12.02亿元，同比上升1911.35%；扣非净利润3.21亿元，同比上升137.92%；其中2025年第三季度，公司单季度主营收入8.06亿元，同比上升13.9%；单季度归母净利润9.84亿元，同比上升499.86%；单季度扣非净利润1.01亿元，同比下降72.37%；负债率12.46%，投资收益11.73亿元，财务费用1378.34万元，毛利率71.89%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600025814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600867"],"gpt_icon":0},{"id":"1191545110","title":"通化东宝预计2025年将实现净利润约12亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191545110","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191545110?lang=zh_cn&edition=full","pubTime":"2026-01-26 17:19","pubTimestamp":1769419145,"startTime":"0","endTime":"0","summary":"通化东宝表示，公司预计在2025年能够恢复盈利，实现归属于母公司股东的净利润约为12亿元人民币。这一积极预期反映了公司在产品管线优化和市场拓展方面的持续努力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0188","BK0196","600867"],"gpt_icon":0},{"id":"2604925920","title":"每周股票复盘：通化东宝（600867）东宝集团质押股份占总股本29.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604925920","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604925920?lang=zh_cn&edition=full","pubTime":"2026-01-18 04:06","pubTimestamp":1768680371,"startTime":"0","endTime":"0","summary":"通化东宝药业股份有限公司控股股东东宝集团于2026年1月13日至14日解除质押55,350,000股，并于同日将相同数量股份重新质押给中国银行股份有限公司通化分行，用于补充流动资金。通化东宝药业股份有限公司控股股东东宝集团于2026年1月13日解除质押股份28,000,000股，占其所持股份比例4.52%。本次解押及再质押后，东宝集团累计质押股份574,439,472股，占其所持股份的92.73%，占公司总股本的29.33%。东宝集团及其一致行动人合计质押股份占其持股总数的89.57%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0196","600867"],"gpt_icon":0},{"id":"2603994082","title":"通化东宝（600867）披露控股股东股份解押及再质押公告，1月16日股价下跌0.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603994082","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603994082?lang=zh_cn&edition=full","pubTime":"2026-01-16 22:48","pubTimestamp":1768574895,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，通化东宝报收于8.5元，较前一交易日下跌0.7%，最新总市值为166.48亿元。公司近日发布公告称，控股股东东宝集团于2026年1月13日解除质押股份28,000,000股，占其所持股份比例4.52%。随后于2026年1月15日再次质押40,000,000股，占其所持股份比例6.46%，质押用途为偿还债务。本次解押及再质押后，东宝集团累计质押股份574,439,472股，占其所持股份的92.73%，占公司总股本的29.33%。东宝集团及其一致行动人合计质押股份占其持股总数的89.57%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600041493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0196","600867"],"gpt_icon":0},{"id":"2603598618","title":"通化东宝（600867）公司公告聘任高级管理人员，1月15日股价上涨0.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603598618","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603598618?lang=zh_cn&edition=full","pubTime":"2026-01-15 22:36","pubTimestamp":1768487772,"startTime":"0","endTime":"0","summary":"截至2026年1月15日收盘，通化东宝报收于8.56元，较前一交易日上涨0.47%，最新总市值为167.65亿元。该股当日开盘8.51元，最高8.6元，最低8.46元，成交额达1.35亿元，换手率为0.81%。近日，通化东宝发布关于聘任高级管理人员的公告。公告称，公司于2026年1月15日召开第十一届董事会第二十一次会议，审议通过聘任关东亮先生、范朴先生为公司副总裁。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500041158.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","600867","BK0239"],"gpt_icon":0},{"id":"2601639848","title":"通化东宝（600867）披露关于审计机构变更签字项目合伙人、签字注册会计师的公告，1月8日股价上涨0.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601639848","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601639848?lang=zh_cn&edition=full","pubTime":"2026-01-08 22:34","pubTimestamp":1767882860,"startTime":"0","endTime":"0","summary":"截至2026年1月8日收盘，通化东宝报收于8.45元，较前一交易日上涨0.24%，最新总市值为165.5亿元。公司近日发布公告称，通化东宝药业股份有限公司于2025年10月17日和11月3日分别召开董事会及临时股东会，审议通过聘任大信会计师事务所为公司2025年度财务报告及内部控制审计机构。近日，公司收到大信会计师事务所通知，因内部工作安排，原签字项目合伙人李楠女士变更为王树奇先生，原签字注册会计师王博先生变更为张忠伟先生。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800039206.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600867","BK0239","BK0188","BK0196"],"gpt_icon":0},{"id":"2601874696","title":"通化东宝（600867）股东东宝实业集团股份有限公司质押4200万股，占总股本2.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601874696","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601874696?lang=zh_cn&edition=full","pubTime":"2026-01-07 18:35","pubTimestamp":1767782149,"startTime":"0","endTime":"0","summary":"证券之星消息，通化东宝1月7日公开信息显示，股东东宝实业集团股份有限公司向中国银行股份有限公司通化分行、中国工商银行股份有限公司通化县支行合计质押4200.0万股，占总股本2.14%。质押详情见下表：截止本公告日，股东东宝实业集团股份有限公司已累计质押股份5.62亿股，占其持股总数的90.79%。通化东宝主营业务：药品研发、生产和销售,主要业务涵盖生物制品、中成药、化学药,治疗领域以糖尿病及内分泌、心脑血管为主。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700031236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","600867","BK0239","BK0188"],"gpt_icon":0},{"id":"2601008580","title":"通化东宝（600867）披露以集中竞价交易方式回购公司股份进展公告，1月5日股价上涨2.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601008580","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601008580?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:10","pubTimestamp":1767607828,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，通化东宝报收于8.38元，较前一交易日上涨2.57%，最新总市值为164.13亿元。公司近日发布公告，披露了以集中竞价交易方式回购公司股份的最新进展。根据公告，通化东宝药业股份有限公司于2025年10月17日召开董事会，审议通过以集中竞价交易方式回购公司股份的方案，回购资金总额为2,000万元至4,000万元，回购价格不超过10元/股，回购期限为2025年10月17日至2026年4月16日，回购股份拟用于员工持股计划或股权激励。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500027805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600867","BK0188","BK0196"],"gpt_icon":0},{"id":"2600036485","title":"每周股票复盘：通化东宝（600867）控股股东累计质押占总股本28.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600036485","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600036485?lang=zh_cn&edition=full","pubTime":"2026-01-02 03:10","pubTimestamp":1767294621,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，通化东宝报收于8.33元，较上周的8.43元下跌1.19%。本周，通化东宝12月22日盘中最高价报8.45元。通化东宝关于控股股东股份解押及再质押公告通化东宝药业股份有限公司控股股东东宝集团于2025年12月26日解除质押股份53,000,000股，占其所持股份比例8.56%。本次解押及再质押后，东宝集团累计质押股份562,439,472股，占其所持股份的90.79%，占公司总股本的28.72%。东宝集团及其一致行动人合计质押股份占其持股总数的87.69%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","600867","BK0196"],"gpt_icon":0},{"id":"2595993797","title":"通化东宝（600867）股东东宝实业集团股份有限公司质押4950万股，占总股本2.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595993797","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595993797?lang=zh_cn&edition=full","pubTime":"2025-12-30 18:41","pubTimestamp":1767091294,"startTime":"0","endTime":"0","summary":"证券之星消息，通化东宝12月30日公开信息显示，股东东宝实业集团股份有限公司向吉林银行股份有限公司通化新华支行合计质押4950.0万股，占总股本2.53%。质押详情见下表：截止本公告日，股东东宝实业集团股份有限公司已累计质押股份5.62亿股，占其持股总数的90.79%。通化东宝主营业务：药品研发、生产和销售,主要业务涵盖生物制品、中成药、化学药,治疗领域以糖尿病及内分泌、心脑血管为主。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000032677.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0188","BK0239","600867"],"gpt_icon":0},{"id":"2595373516","title":"通化东宝（600867）披露研发生产系统员工持股计划完成股票非交易过户，12月29日股价下跌1.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595373516","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595373516?lang=zh_cn&edition=full","pubTime":"2025-12-29 22:20","pubTimestamp":1767018030,"startTime":"0","endTime":"0","summary":"截至2025年12月29日收盘，通化东宝报收于8.21元，较前一交易日下跌1.44%，最新总市值为160.8亿元。公司近日发布公告称，通化东宝药业股份有限公司于2025年12月26日完成研发生产系统员工持股计划的股票非交易过户，过户股份数量为637.00万股，占公司总股本的0.325%，过户价格为4.39元/股。员工持股计划存续期为60个月，首次授予的股票分三期解锁，分别在过户后满12、24、36个月解锁40%、30%、30%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900037788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600867","BK0239","BK0196"],"gpt_icon":0},{"id":"2588880812","title":"通化东宝（600867）披露研发生产系统员工持股计划草案，12月4日股价下跌0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588880812","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588880812?lang=zh_cn&edition=full","pubTime":"2025-12-04 22:11","pubTimestamp":1764857479,"startTime":"0","endTime":"0","summary":"截至2025年12月4日收盘，通化东宝报收于8.76元，较前一交易日下跌0.68%，最新总市值为171.57亿元。公司近日发布公告，披露将召开2025年第四次临时股东会，审议《研发生产系统员工持股计划（草案）》及其摘要、《员工持股计划管理办法》等相关议案。根据公告内容，本次员工持股计划的参与对象为公司研发生产系统的核心骨干人员，首次授予人数不超过122人，拟持有标的股票总数为700万股，占公司总股本的0.357%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400039476.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600867","BK0188","BK0196"],"gpt_icon":0},{"id":"2588059576","title":"通化东宝（600867）披露以集中竞价交易方式回购公司股份进展公告，12月02日股价下跌0.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588059576","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588059576?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:13","pubTimestamp":1764684789,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘，通化东宝报收于8.74元，较前一交易日下跌0.23%，最新总市值为171.18亿元。公司近日发布公告称，通化东宝药业股份有限公司于2025年10月17日召开董事会，审议通过以集中竞价交易方式回购公司股份的方案，回购资金总额不低于2,000万元且不超过4,000万元，回购价格不超过10元/股，回购期限为2025年10月17日至2026年4月16日，回购股份拟用于员工持股计划或股权激励。上述回购进展符合相关规定及公司回购方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200039473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600867","BK0188","BK0239","BK0196"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773186687693,"stockEarnings":[{"period":"1week","weight":0.0327},{"period":"1month","weight":0.0292},{"period":"3month","weight":0.0492},{"period":"6month","weight":0.0865},{"period":"1year","weight":0.2527},{"period":"ytd","weight":0.1224}],"compareEarnings":[{"period":"1week","weight":0.0001},{"period":"1month","weight":0.0142},{"period":"3month","weight":0.0571},{"period":"6month","weight":0.064},{"period":"1year","weight":0.2249},{"period":"ytd","weight":0.0389}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"通化东宝药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"82143人(较上一季度减少5.08%)","perCapita":"23843股","listingDate":"1994-08-24","address":"吉林省通化市通化县东宝新村","registeredCapital":"195854万元","survey":" 通化东宝药业股份有限公司的主营业务是糖尿病及内分泌治疗领域生物制品、中成药、化学药等药品的研发、生产和销售。公司的主要产品是人胰岛素原料药、人胰岛素注射剂（注册商标：甘舒霖）、甘精胰岛素原料药、甘精胰岛素注射液（注册商标：平舒霖）、门冬胰岛素原料药、门冬胰岛素注射液、预混型门冬胰岛素（门冬胰岛素30注射液与门冬胰岛素50注射液）（注册商标：锐舒霖）、利拉鲁肽注射液（注册商标：统博力）、恩格列净片（注册商标：唐捷恩）、镇脑宁胶囊、糖尿病。公司被国家认定为高新技术企业、国家技术创新示范企业。","listedPrice":6.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"通化东宝(600867)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供通化东宝(600867)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"通化东宝,600867,通化东宝股票,通化东宝股票老虎,通化东宝股票老虎国际,通化东宝行情,通化东宝股票行情,通化东宝股价,通化东宝股市,通化东宝股票价格,通化东宝股票交易,通化东宝股票购买,通化东宝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"通化东宝(600867)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供通化东宝(600867)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}